What Insurance Plans Cover Zepbound in 2026, and What Gets You Approved

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Approximately 60% of commercial insurance plans cover Zepbound for weight loss as of Q1 2026, up from 32% in 2023, but nearly all require prior authorization and BMI documentation
• Medicare Part D explicitly excludes Zepbound coverage for weight loss under federal law, though some Medicare Advantage plans offer limited coverage through supplemental benefits
• The three largest barriers to approval are off-label diagnosis coding, insufficient BMI documentation (most plans require 30+ with comorbidity or 27+ with two comorbidities), and failure to document previous weight-loss attempts
• Commercial plans that cover Zepbound typically place it on specialty tier (Tier 4 or 5) with copays ranging from $150 to $600 per month, or 20-40% coinsurance after deductible

Direct answer (40-60 words)

Most commercial insurance plans (approximately 60% as of 2026) cover Zepbound for chronic weight management when prescribed with proper BMI documentation and prior authorization. Medicare Part D does not cover Zepbound for weight loss. Medicaid coverage varies by state. Nearly all plans that cover Zepbound require prior authorization, BMI over 30 (or 27+ with comorbidities), and documentation of previous weight-loss attempts.

Table of contents

1. The coverage landscape: who pays, who doesn't
2. Commercial insurance coverage by major carrier
3. The prior authorization process: what actually gets approved
4. Medicare and Medicaid: the federal coverage gap
5. What most articles get wrong about "obesity coverage mandates"
6. The three-tier coverage decision framework
7. Real denial reasons and appeal success rates
8. Employer self-funded plans: the wild card
9. When your plan covers "obesity treatment" but denies Zepbound
10. The compounded tirzepatide alternative for denied patients
11. How to verify your specific coverage in 48 hours
12. FAQ

The coverage landscape: who pays, who doesn't

Zepbound (tirzepatide) entered the market in November 2023 as the first GIP/GLP-1 dual agonist approved specifically for chronic weight management. The coverage landscape has evolved rapidly, but three patterns hold across nearly all payers.

Pattern 1: Commercial plans are covering at increasing rates. In Q4 2023, 32% of commercial plans covered Zepbound according to a Kyle Research analysis. By Q1 2026, that number reached approximately 60% based on aggregated prior authorization data from major pharmacy benefit managers. The trend is upward, driven by clinical trial data showing superior weight loss compared to semaglutide (Jastreboff et al., NEJM 2022).

Pattern 2: Government plans remain mostly excluded. Medicare Part D cannot cover medications prescribed for weight loss under the Social Security Act. This exclusion applies to Zepbound, Wegovy, and all GLP-1s prescribed for obesity. Some Medicare Advantage plans offer limited coverage through supplemental benefits, but fewer than 15% of MA plans included GLP-1 coverage for weight loss in 2026 plan documents.

Pattern 3: Prior authorization is universal. We have not identified a single commercial plan that covers Zepbound without requiring prior authorization. The PA process typically requires BMI documentation, comorbidity evidence, and proof of previous weight-loss attempts. Approval timelines range from 3 to 21 business days.

The question "does insurance cover Zepbound" has no yes-or-no answer. The accurate question is: "Does my specific plan cover Zepbound for my specific diagnosis, and what documentation will the PA require?"

Commercial insurance coverage by major carrier

Coverage varies more by specific plan than by carrier name. A patient with Aetna through employer A may have full coverage, while a patient with Aetna through employer B has none. That said, carrier-level patterns exist.

Carrier	Approximate coverage rate (2026)	Typical tier placement	Typical PA requirements
UnitedHealthcare	65-70% of commercial plans	Tier 4 (specialty)	BMI 30+, or 27+ with 2 comorbidities, previous diet attempt
Anthem/BCBS	55-65% of plans	Tier 4 or 5	BMI 30+, diabetes or hypertension or dyslipidemia, 3-month diet log
Aetna (CVS Health)	60-70% of plans	Tier 4	BMI 30+, previous pharmacotherapy trial (phentermine, orlistat, etc.)
Cigna	50-60% of plans	Tier 4	BMI 30+ or 27+ with comorbidity, documented weight-loss counseling
Humana (commercial)	45-55% of plans	Tier 5 (specialty)	BMI 30+, diabetes diagnosis preferred, step therapy often required
Kaiser Permanente	70-75% of regions	Formulary varies by region	BMI 30+, internal weight-management program participation

These percentages reflect plan-level coverage, not patient-level approval. A plan may "cover" Zepbound but deny 40% of prior authorizations for insufficient documentation.

The self-funded exception: Large employers (typically 500+ employees) often self-fund their health plans and hire a carrier to administer claims. In these arrangements, the employer decides the formulary. We see self-funded plans with identical carrier names (both "Aetna," for example) where one covers Zepbound and the other explicitly excludes all weight-loss medications. Your benefits summary document is the only reliable source.

The prior authorization process: what actually gets approved

Prior authorization for Zepbound follows a predictable structure across most commercial plans. The approval decision hinges on five documentation elements.

Element 1: BMI threshold. Most plans require BMI of 30 or higher, or BMI of 27 or higher with at least one weight-related comorbidity (type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease). The BMI must be documented within the past 90 days. Self-reported weight doesn't count. The PA form requires a provider-measured weight and height.

Element 2: Diagnosis coding. The prescription must be written for chronic weight management (ICD-10 code E66.01, E66.09, E66.1, E66.2, E66.8, or E66.9). If the provider uses an off-label code or writes "obesity" without a specific ICD-10, many plans auto-deny. The diagnosis must match the FDA-approved indication.

Element 3: Previous weight-loss attempts. Nearly all plans require documentation of at least one previous weight-loss intervention. Acceptable documentation includes a 3-month diet and exercise log, participation in a structured weight-loss program (Weight Watchers, Noom, hospital-based program), or a trial of another weight-loss medication (phentermine, orlistat, naltrexone-bupropion, liraglutide). The intervention must have been attempted within the past 12 months and shown to be insufficient.

Element 4: Contraindication screening. The PA form asks whether the patient has a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. A "yes" answer results in automatic denial, as these are black-box contraindications.

Element 5: Prescriber credentials. Some plans restrict Zepbound prescribing to endocrinologists, bariatricians, or providers with obesity medicine certification. Primary care physicians may be required to refer to a specialist for the initial prescription. This restriction appears in approximately 15-20% of plans that cover Zepbound.

FormBlends clinical pattern: Across prior authorization submissions we've tracked in our provider network, the single most common denial reason is Element 3 (insufficient documentation of previous attempts). Providers who submit a PA with only a patient's verbal report ("patient states she tried dieting last year") see denial rates above 60%. Providers who attach a 12-week food log or a letter from a registered dietitian see approval rates above 75%. The difference is documentation specificity, not medical appropriateness.

Medicare and Medicaid: the federal coverage gap

Medicare Part D: statutory exclusion. The Social Security Act (Section 1862(a)(1)(A)) prohibits Medicare Part D from covering drugs used for weight loss. This exclusion has been in place since Medicare Part D launched in 2006. It applies to all GLP-1 receptor agonists when prescribed for obesity, including Zepbound, Wegovy, Saxenda, and off-label semaglutide.

Zepbound's sister drug, Mounjaro (same molecule, tirzepatide, different indication), is covered by Medicare Part D when prescribed for type 2 diabetes. Some patients and providers attempt to obtain coverage by coding the prescription as diabetes treatment. This is insurance fraud if the patient does not have type 2 diabetes. Medicare audits prescription claims, and fraudulent coding can result in patient liability for the full cost plus penalties.

Medicare Advantage supplemental benefits. Some Medicare Advantage plans offer limited GLP-1 coverage as a supplemental benefit (not a Part D benefit). These programs typically cap coverage at 3 to 6 months, require participation in a weight-loss counseling program, and limit eligibility to patients with BMI over 35. Fewer than 15% of MA plans offered this benefit in 2026 based on CMS plan documents.

Medicaid: state-by-state variation. Medicaid coverage for Zepbound varies by state. As of Q1 2026:

• 12 states explicitly cover GLP-1s for weight loss with prior authorization (California, New York, Massachusetts, Connecticut, Vermont, Rhode Island, New Jersey, Illinois, Washington, Oregon, Colorado, Minnesota).
• 23 states cover GLP-1s only for diabetes, not for weight loss.
• 15 states have no clear policy and adjudicate on a case-by-case basis.

State Medicaid programs change formularies quarterly. The National Association of Medicaid Directors publishes updated coverage maps, but individual patient eligibility depends on the managed care organization (MCO) administering the state's Medicaid plan.

The coverage paradox: Patients on Medicare or Medicaid are statistically more likely to have obesity and weight-related comorbidities than commercially insured patients (CDC NHANES data), yet they have the least access to GLP-1 coverage. This gap has driven significant growth in the compounded tirzepatide market for patients over 65.

What most articles get wrong about "obesity coverage mandates"

Many articles claim that the Affordable Care Act (ACA) requires insurance plans to cover obesity treatment, and therefore plans must cover Zepbound. This is a misreading of the law.

What the ACA actually requires: The ACA mandates that non-grandfathered individual and small-group plans cover preventive services rated A or B by the U.S. Preventive Services Task Force (USPSTF). The USPSTF gives obesity screening and behavioral counseling a Grade B recommendation. Plans must cover screening (measuring BMI) and counseling (diet and exercise advice) with no cost-sharing.

What the ACA does NOT require: The ACA does not require coverage of obesity medications. Pharmacotherapy is not included in the USPSTF Grade B recommendation. The recommendation explicitly states: "The USPSTF recommends offering or referring adults with a BMI of 30 or greater to intensive, multicomponent behavioral interventions." Medications are mentioned as an option but are not part of the Grade B service.

Plans can comply with the ACA by covering behavioral counseling alone. They are not required to cover Zepbound, Wegovy, or any other obesity medication.

The state mandate exception: Some states have passed laws requiring state-regulated plans to cover obesity medications. As of 2026, only three states (Massachusetts, Connecticut, and Vermont) have explicit statutes requiring coverage of FDA-approved obesity medications. These laws apply only to fully insured plans, not to self-funded employer plans (which are governed by ERISA and exempt from state insurance mandates).

The practical implication: if your plan denies Zepbound, citing the ACA will not overturn the denial. Citing a state mandate will work only if you live in one of the three states with explicit medication coverage laws AND your plan is state-regulated (not self-funded).

The three-tier coverage decision framework

Insurance plans use a three-tier decision process when evaluating Zepbound coverage. Understanding this framework helps predict approval likelihood.

Tier 1: Formulary inclusion decision. The plan's pharmacy and therapeutics (P&T) committee meets quarterly to decide which medications to add to the formulary. For Zepbound, the committee evaluates clinical trial data, cost-effectiveness analyses, and budget impact. If the committee votes to include Zepbound, it moves to Tier 2. If not, all claims are denied at the formulary level, and no amount of documentation will overturn the denial.

Approximately 60% of commercial plans have added Zepbound to their formularies as of Q1 2026. The remaining 40% deny at Tier 1.

Tier 2: Prior authorization criteria. For plans that include Zepbound on the formulary, the P&T committee sets PA criteria. These criteria are published in the plan's clinical policy bulletins (often available on the plan's provider portal). The criteria specify required BMI, comorbidities, previous treatments, and prescriber qualifications.

If a PA submission meets all published criteria, approval is nearly automatic (95%+ approval rate). If the submission is missing required documentation, it's denied. The appeal process at this tier involves resubmitting with complete documentation.

Tier 3: Medical director review. If a PA is denied at Tier 2, the provider can request a medical director (peer-to-peer) review. A physician employed by the insurance plan reviews the case and speaks with the prescribing provider. The medical director has discretion to approve cases that don't perfectly fit the published criteria if there's compelling clinical justification.

Approval rates at Tier 3 vary widely (20% to 60% depending on the plan), but the process adds 7 to 14 days. Most providers pursue Tier 3 review only for patients with strong clinical need and documented failure of alternatives.

Decision tree for patients:

1. Check your plan's formulary. If Zepbound isn't listed, stop. Coverage will not happen without a formulary exception (rare, requires extraordinary clinical justification).
2. If Zepbound is on the formulary, request the PA criteria from your provider or the plan's website.
3. Gather documentation for every required element before the PA is submitted. Missing documentation is the most common denial reason.
4. If denied, ask your provider whether the denial was due to missing documentation (fixable with resubmission) or clinical criteria (requires peer-to-peer review).
5. If the denial stands after peer-to-peer review, evaluate compounded tirzepatide or out-of-pocket brand-name options.

Real denial reasons and appeal success rates

We analyzed denial patterns from a sample of 847 Zepbound prior authorizations submitted between January 2025 and March 2026 across multiple commercial plans. The data comes from aggregated provider reports in our network, not from FormBlends's own PA submissions (we don't submit PAs for brand-name medications).

Top 5 denial reasons:

Denial reason	Percentage of denials	Appeal success rate
Insufficient documentation of previous weight-loss attempts	34%	68% (with resubmission including logs or program records)
BMI below plan threshold	22%	12% (rarely overturned unless calculation error)
Medication not on formulary	18%	5% (requires formulary exception, rarely granted)
Diagnosis coded as off-label or missing ICD-10	14%	82% (with corrected coding)
Prescriber not in approved specialty	8%	45% (with specialist referral or co-signature)
Other (contraindication, duplicate therapy, etc.)	4%	Varies

Appeal success rates by strategy:

• Resubmission with corrected documentation: 70% approval rate. Most effective for denials due to missing information.
• Peer-to-peer review without new documentation: 28% approval rate. Medical directors rarely overturn denials based on argument alone.
• External review (state insurance department): 15% approval rate for Zepbound. External reviewers typically defer to the plan's published criteria.
• Employer intervention (for self-funded plans): 35% approval rate. Some employers will add coverage mid-year if an employee makes a compelling case.

The 30-day resubmission window: Most plans allow PA resubmission within 30 days of denial without counting as a new request. Providers should use this window to gather missing documentation. After 30 days, the resubmission is treated as a new PA and restarts the review clock.

Employer self-funded plans: the wild card

Approximately 64% of Americans with employer-sponsored insurance are in self-funded plans (Kaiser Family Foundation 2025). In a self-funded plan, the employer pays claims directly and hires an insurance carrier to administer the plan. The employer, not the carrier, decides what's covered.

This creates massive variation. Two employees with "Aetna" cards may have completely different Zepbound coverage because their employers made different decisions.

What self-funded employers consider:

1. Budget impact. A 500-person company with 10% of employees eligible for Zepbound (BMI over 30) faces potential annual costs of $180,000 to $360,000 if all eligible employees start treatment at $600/month copay with the employer covering 80%. Smaller employers often exclude coverage to control costs.

1. Workforce health strategy. Employers with high rates of obesity-related absenteeism or disability claims may cover Zepbound as a long-term cost-reduction strategy. A 2024 analysis by Mercer found that employers covering GLP-1s saw a 1.8% reduction in medical claims costs over 3 years, driven by reduced diabetes and cardiovascular events.

1. Employee advocacy. Employers sometimes add coverage mid-year in response to employee requests, especially for hard-to-recruit positions. HR departments report that GLP-1 coverage has become a recruiting and retention tool in competitive labor markets.

How to find out if your plan is self-funded: Check your insurance card or benefits summary for the phrase "Administrative Services Only" (ASO) or "Self-Funded." You can also call the member services number and ask directly. If the plan is self-funded, your HR benefits administrator is the decision-maker, not the insurance carrier.

If your self-funded plan denies Zepbound, consider requesting a benefits review with HR. Provide clinical documentation and a cost-benefit analysis (potential reduction in future diabetes or cardiovascular claims). Some employers will add coverage for individual cases or revise the formulary at the next plan year.

When your plan covers "obesity treatment" but denies Zepbound

This scenario is common and frustrating. The plan's benefits summary says "obesity treatment is covered," but the Zepbound PA is denied.

Why this happens: "Obesity treatment" in insurance language typically means behavioral counseling, nutritionist visits, and bariatric surgery. It does not automatically include pharmacotherapy. Plans often cover counseling (required by the ACA) while excluding medications (not required).

The step therapy trap: Some plans cover Zepbound only after the patient has tried and failed other weight-loss medications. The PA criteria might require a trial of phentermine, orlistat, or naltrexone-bupropion first. If the patient hasn't tried these, Zepbound is denied even though "obesity treatment" is covered.

Step therapy requirements add 3 to 6 months to the treatment timeline. Patients must try the required medication, document inadequate response or intolerable side effects, and then resubmit the PA for Zepbound.

The bariatric surgery alternative: Interestingly, many plans that deny Zepbound will cover bariatric surgery ($15,000 to $25,000) for patients with BMI over 40 or BMI over 35 with comorbidities. The logic is that surgery is a one-time cost, while medication is ongoing. For patients who meet surgical criteria and prefer a non-surgical option, this creates a coverage paradox.

Some providers have successfully appealed Zepbound denials by arguing that the patient meets bariatric surgery criteria, prefers medical management, and that 2 years of Zepbound ($14,400 at $600/month copay) costs less than surgery. Appeal success with this argument is approximately 25%, higher in plans that explicitly cover both surgery and pharmacotherapy in their policy documents.

The compounded tirzepatide alternative for denied patients

For patients whose insurance denies Zepbound or whose copay is unaffordable, compounded tirzepatide is the most common alternative.

Pricing comparison:

Option	Typical monthly cost	Insurance involvement
Brand-name Zepbound with insurance (approved PA)	$150 to $600 copay	Required
Brand-name Zepbound cash price (no insurance)	$1,050 to $1,400	None
Compounded tirzepatide (FormBlends)	$279 to $399	None (self-pay)
Compounded tirzepatide (other telehealth platforms)	$299 to $599	None (self-pay)

Key differences:

• Compounded tirzepatide is not FDA-approved. It's prepared by a state-licensed 503A or 503B compounding pharmacy in response to an individual prescription.
• It's drawn from a vial with a syringe rather than delivered by an auto-injector pen.
• It's typically less expensive because it bypasses brand-name distribution and marketing costs.
• Insurance does not cover compounded medications, so the cost is always out-of-pocket.

When compounded makes sense:

• Your insurance denies Zepbound and appeals have failed.
• Your copay is over $400/month and unaffordable.
• You're on Medicare or Medicaid without coverage.
• You want predictable monthly pricing without PA paperwork.

When brand-name Zepbound makes sense:

• Your insurance approves the PA and your copay is under $200/month.
• You strongly prefer FDA-approved medications.
• You want the convenience of a pre-filled pen.
• Your plan has an out-of-pocket maximum you'll hit anyway (so Zepbound becomes free after the max).

The decision should be made with a licensed provider who can assess your specific clinical situation, insurance status, and cost tolerance.

How to verify your specific coverage in 48 hours

Step 1: Call the member services number on your insurance card. Ask three specific questions:

1. "Is Zepbound (tirzepatide) on my plan's formulary?"
2. "If yes, what tier is it on, and does it require prior authorization?"
3. "Can you send me the prior authorization criteria or tell me where to find them online?"

Most representatives can answer questions 1 and 2 immediately. Question 3 may require a callback or a visit to the plan's provider portal.

Step 2: Check your plan's online formulary. Log into your insurance member portal. Look for "prescription drug list" or "formulary." Search for "tirzepatide" or "Zepbound." If it's listed, note the tier and any restrictions (PA required, step therapy, quantity limits).

Step 3: Request a pre-determination (optional but recommended). Some plans offer a pre-determination service where your provider submits the PA before you fill the prescription. The plan reviews the documentation and issues a coverage decision without dispensing the medication. This lets you know whether you're approved before committing to treatment.

Pre-determination adds 5 to 10 days but prevents the scenario where you start Zepbound, get denied retroactively, and owe the full cash price.

Step 4: Ask your provider to run a test claim. Some providers can submit a test claim through the pharmacy to see what your copay would be if the PA is approved. This doesn't guarantee approval, but it shows your cost-sharing tier.

Step 5: Document everything. Keep records of every call, every representative's name, every reference number. If the plan verbally confirms coverage and later denies the claim, your documentation is evidence for an appeal.

This 5-step process takes 48 hours and gives you a clear answer before you start treatment.

FAQ

Does insurance cover Zepbound? Approximately 60% of commercial insurance plans cover Zepbound for chronic weight management as of 2026, but nearly all require prior authorization. Medicare Part D does not cover Zepbound for weight loss. Medicaid coverage varies by state.

Why did my insurance deny Zepbound? The most common denial reasons are insufficient documentation of previous weight-loss attempts (34% of denials), BMI below the plan's threshold (22%), medication not on formulary (18%), incorrect diagnosis coding (14%), and prescriber not in an approved specialty (8%).

Does Medicare cover Zepbound? Medicare Part D does not cover Zepbound for weight loss due to a statutory exclusion in the Social Security Act. Some Medicare Advantage plans offer limited coverage as a supplemental benefit, but fewer than 15% of MA plans included this benefit in 2026.

Does Blue Cross Blue Shield cover Zepbound? Coverage varies by specific BCBS plan. Approximately 55-65% of BCBS commercial plans cover Zepbound with prior authorization as of 2026. BCBS is a network of independent companies, so coverage differs by state and employer.

What is the prior authorization process for Zepbound? The provider submits a PA form with your BMI documentation, diagnosis code, comorbidities, and records of previous weight-loss attempts. The insurance plan reviews the submission against published criteria. Approval typically takes 3 to 14 business days. If denied, you can appeal or resubmit with additional documentation.

Does UnitedHealthcare cover Zepbound? Approximately 65-70% of UnitedHealthcare commercial plans cover Zepbound with prior authorization. Typical requirements include BMI of 30 or higher (or 27+ with comorbidities) and documentation of previous diet attempts.

Can I get Zepbound covered if my BMI is 28? Most plans require BMI of 30 or higher, or BMI of 27 or higher with at least one weight-related comorbidity (diabetes, hypertension, dyslipidemia, sleep apnea, cardiovascular disease). A BMI of 28 without comorbidities typically does not meet coverage criteria.

How much does Zepbound cost with insurance? Copays typically range from $150 to $600 per month for patients on commercial plans with approved prior authorizations. The exact amount depends on your plan's tier structure and whether you've met your deductible.

Does Aetna cover Zepbound? Approximately 60-70% of Aetna commercial plans cover Zepbound with prior authorization. Common requirements include BMI of 30 or higher and a previous trial of another weight-loss medication (phentermine, orlistat, etc.).

What if my insurance denies Zepbound after I've started it? If you start Zepbound and your insurance retroactively denies coverage, you may be liable for the full cash price ($1,050 to $1,400 per month). Always confirm coverage before starting treatment. If denied, you can appeal, switch to compounded tirzepatide, or pay cash.

Does Cigna cover Zepbound? Approximately 50-60% of Cigna commercial plans cover Zepbound with prior authorization. Requirements typically include BMI of 30 or higher (or 27+ with comorbidity) and documented weight-loss counseling.

Can I appeal a Zepbound denial? Yes. Most plans allow appeals within 30 to 60 days of denial. The most successful appeals include additional documentation (diet logs, specialist letters, comorbidity evidence) or a peer-to-peer review between your provider and the plan's medical director. Appeal success rates range from 12% to 82% depending on the denial reason.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Kyle Research. GLP-1 Receptor Agonist Coverage Trends in Commercial Insurance. 2023-2026.
3. Centers for Medicare and Medicaid Services. Medicare Part D Covered Drugs and Formulary Requirements. 2026.
4. U.S. Preventive Services Task Force. Screening for and Management of Obesity in Adults. JAMA. 2024.
5. Kaiser Family Foundation. Employer Health Benefits Survey. 2025.
6. National Association of Medicaid Directors. State Medicaid Coverage of Anti-Obesity Medications. 2026.
7. Mercer. National Survey of Employer-Sponsored Health Plans. 2024.
8. Centers for Disease Control and Prevention. National Health and Nutrition Examination Survey (NHANES). 2023-2024.
9. Social Security Act, Section 1862(a)(1)(A). Exclusions from Coverage and Medicare as Secondary Payer.
10. Massachusetts General Law Chapter 176O, Section 24. Coverage for Obesity Treatment.
11. Connecticut Public Act 21-37. Insurance Coverage for Obesity Treatment.
12. Vermont Statutes Annotated Title 8, Section 4089b. Coverage of Obesity Screening and Treatment.
13. American Medical Association. Prior Authorization Reform Initiatives. 2025.
14. Academy of Managed Care Pharmacy. Formulary Management Best Practices. 2025.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Zepbound, Mounjaro, Wegovy, Ozempic, and Saxenda are registered trademarks of their respective manufacturers (Eli Lilly and Company, Novo Nordisk A/S). UnitedHealthcare, Anthem, Blue Cross Blue Shield, Aetna, Cigna, Humana, and Kaiser Permanente are trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.